FLUCELVAX QUADRIVALENT Rx
Generic Name and Formulations:
Quadrivalent, inactivated, "subunit" influenza vaccine (virus types A and B); contains a total of 60mcg of hemagglutinin per 0.5mL dose; formulation changes annually; susp for IM inj; antibiotic-free.
Indications for FLUCELVAX QUADRIVALENT:
Adults and Children:
<4yrs: not established. Each dose is 0.5mL by IM inj once in the deltoid. 4–8yrs: 1 or 2 doses at least 4wks apart (depending on vaccination history as per annual ACIP recommendation). ≥9yrs: 1 dose.
Use current formulation only. Have appropriate medical treatment and supervision readily available. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Pregnancy (Cat.B). Nursing mothers.
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants: may get suboptimal response.
Local reactions (eg, pain, erythema, induration), headache, fatigue, myalgia; syncope.
Single-dose prefilled syringe 0.5mL (preservative-free)—10 (without needles); Multi-dose vial 5mL (contains thimerosal)—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|